Background: The purpose of this study is to assess the efficacy and safety of combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma (MPM). Patients and Methods: Patients with untreated, advanced, or metastatic MPM who meet the inclusion and exclusion criteria will be included. A total of 18 patients will be enrolled from 4 Japanese institutions within 1 year. Combination chemotherapy with cisplatin (75 mg/m 2 ), pemetrexed (500 mg/m 2 ), and nivolumab (360 mg/person) is administered every 3 weeks for
Introduction
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that arises from mesothelial-lined surfaces and has a poor survival rate. 1 MPM occurs more frequently in men (80%) than in women, and the peak age of onset is between 60 and 80 years old. 2 The industrial use of asbestos has been banned in Japan since 2006, but the incidence of MPM is expected to continue to increase for the next few decades because of the past usage of asbestos. 3 Treatment of MPM is challenging. Most of the cases are diagnosed at an advanced stage and are treated with systemic chemotherapy. Combination chemotherapy with cisplatin and pemetrexed is the standard treatment regimen; however, the median overall survival (OS) is only approximately 12 .months. 4 Recently, the additional use of bevacizumab improved OS when used with cisplatin and pemetrexed in unresectable MPM. 5 However, the prolongation of the OS was <3
months. In addition, it can be administered only to bevacizumabeligible patients. On the basis of these facts, cisplatin and pemetrexed is still considered the standard treatment regimen, thus, additional treatment options are urgently needed.
Nivolumab is a human monoclonal antibody that targets the programmed death (PD)-1 cluster of differentiation 279 cell surface membrane receptor. Binding of PD-1 to its ligands, PD ligands 1 and 2, results in the downregulation of lymphocyte activation.
Nivolumab inhibits the interaction between PD-1 and its ligands, promotes immune responses, and triggers antitumor activity. It has already been approved by the Ministry of Health, Labor, and Welfare, Japan for multiple types of cancer including malignant melanoma, nonesmall-cell lung cancer, and gastric cancer in Japan. Additionally, a phase II trial showed there was a favorable response with nivolumab for previously treated MPM. 6 A recent report indicated that platinum drugs enhance the effector immune response through modulation of PD-ligand 1. These encouraging results might extend to the first-line treatment of MPM with the hope of enhancing the antitumor response, particularly in combination with the current standard chemotherapy. Unfortunately, no prospective clinical trial is being conducted to evaluate the combination of nivolumab and cisplatin/ pemetrexed. Thus, we launched the current trial to assess combination chemotherapy with cisplatin, pemetrexed, and nivolumab for MPM.
Patients and Methods

Objectives/End Points
This study will assess the efficacy and safety of the first-line combination therapy of cisplatin, pemetrexed, and nivolumab for advanced or metastatic MPM. The primary end point is the centrally reviewed overall response rate. The secondary end points include efficacy evaluated according to the: (1) response rate assessed by investigators; (2) disease control rate; (3) OS; (4) progression-free survival; (5) duration of response; and (6) time to response. Safety and adverse events will also be evaluated.
Study Design/Study Setting
This is a single-arm, prospective, nonrandomized, noncomparative, open-label, multicenter, phase II trial. Figure 1 shows an overview of the study design.
Eligibility Criteria
All patients who meet the main inclusion and exclusion criteria (Tables 1 and 2 ) will be invited for screening. Written informed Cisplatin, Pemetrexed, and Nivolumab for MPM consent must be obtained by an investigator from the patient before any screening or inclusion procedure. This study will be conducted in compliance with the principles of the Declaration of Helsinki, and the protocol was approved by the institutional review board of each of the participating hospitals.
Intervention
Treatment is composed of 2 sequential phases: the combination phase and the maintenance phase. In the former, cisplatin (75 mg/m 2 ), pemetrexed (500 mg/m 2 ), and nivolumab (360 mg/person) will be administered intravenously. Nivolumab was kindly provided by Ono Pharmaceutical Co, Ltd. This treatment will be repeated every 3 weeks with a total of 4 to 6 cycles. If patients have not progressed during the combination phase, maintenance therapy with nivolumab will be administered until disease progression, unacceptable toxicities, or the patient's condition meets the withdrawal criteria.
Nivolumab was administered at a dose of 240 mg/person biweekly in recent clinical trials 6, 8 including the one for MPM that showed encouraging clinical utility and acceptable toxicity profile. 6 Both of cisplatin and pemetrexed are usually administered every 3 weeks. Under the consideration of practical utility and dose intensity, we planned to administer nivolumab every 3 weeks with the dose of 360 mg/person. The combination of nivolumab (10 mg/kg) and pemetrexed/cisplatin every 3 weeks showed an acceptable toxicity profile and encouraging antitumor activity in patients with advanced nonesmall-cell lung cancer. 9 On the basis of these findings, nivolumab will be administered at a dose of 360 mg/person, every 3 weeks, in the current study.
Outcome Measurement/Follow-up
Response is evaluated using the modified Response Evaluation Criteria in Solid Tumors. 10 The OS is defined as the duration from study registration until the date of death or the last patient visit.
Statistical Considerations
The target number of patients is 18 for the current phase II study. If we assume that there would be 6 to 12 patients with a response, the response rate would be 33.3% to 66.7%. In this case, the estimated accuracy indicates the range between the point estimate of the response rate and the lower confidence limit (2-sided 95% confidence coefficient on the basis of exact test) would be 18% to 22%. An OS curve will be constructed using the KaplaneMeier product limit method.
Discussion
There is a medical need for improved treatments for MPM. This study is, to our knowledge, the first clinical trial to evaluate the effect of combining an immune checkpoint inhibitor and platinumbased chemotherapy for MPM. In addition, to our knowledge, this is the first investigator-initiated prospective clinical trial evaluating systemic chemotherapy for MPM that complies with Good Clinical Practice in Japan.
Conclusion
A phase II trial of first-line combination chemotherapy for unresectable MPM commenced in January 2018. This study is, to our knowledge, the first prospective trial to evaluate the effect of an antiePD-1 antibody combined with cisplatin and pemetrexed for unresectable MPM.
